Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + toripalimab (Shanghai Junshi Biosciences Co., Ltd.)
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Capecitabine + toripalimab is a combination therapy being investigated as a maintenance treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC). Toripalimab is a humanized IgG4-κ monoclonal antibody that acts as an immune checkpoint inhibitor by targeting the programmed cell death protein 1 (PD-1) receptor on T cells, thereby restoring anti-tumor immune responses. Capecitabine is an orally administered fluoropyrimidine carbamate prodrug that is enzymatically converted to 5-fluorouracil (5-FU) within tumors. 5-FU inhibits thymidylate synthase, interfering with DNA synthesis and cell division. This combination is specifically being evaluated in a Phase 3 clinical trial (NCT05233358) led by Yan-Qun Xiang at Sun Yat-sen University Cancer Center to improve progression-free survival in NPC patients who have achieved disease control following first-line induction chemotherapy.
- Brand names
- TuoyiXeloda
- Other names
- toripalimab + capecitabine
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on capecitabine + toripalimab (Shanghai Junshi Biosciences Co., Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + toripalimab (Shanghai Junshi Biosciences Co., Ltd.).